Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iBio (IBIO) Operating Expenses (2016 - 2025)

iBio (IBIO) has disclosed Operating Expenses for 16 consecutive years, with $9.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 104.48% to $9.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $25.8 million, a 61.74% increase, with the full-year FY2025 number at $19.0 million, up 12.71% from a year prior.
  • Operating Expenses was $9.4 million for Q4 2025 at iBio, up from $6.1 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $10.6 million in Q4 2022 to a low of $3.6 million in Q2 2024.
  • A 5-year average of $6.5 million and a median of $5.7 million in 2025 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: skyrocketed 177.32% in 2021, then plummeted 57.48% in 2023.
  • iBio's Operating Expenses stood at $7.2 million in 2021, then skyrocketed by 46.22% to $10.6 million in 2022, then crashed by 57.48% to $4.5 million in 2023, then increased by 2.74% to $4.6 million in 2024, then soared by 104.48% to $9.4 million in 2025.
  • Per Business Quant, the three most recent readings for IBIO's Operating Expenses are $9.4 million (Q4 2025), $6.1 million (Q3 2025), and $5.4 million (Q2 2025).